Download BEV3_v2.1_Bevacizumab_1stadvOvarian

National
National Cancer Drugs Fund Application Form –
Bevacizumab
for Advanced Ovarian Cancer
(1st line treatment)
Author(s)
David Thomson
Owner
Chemotherapy Clinical Reference Group
Version Control
Version Control
Date
Revision summary
Ver2.0
14 Jul 2014
Introduction of version control and addition of section re-SACT
and monitoring
Ver2.1
05 Jun 2015
Update of criteria to allow inclusion of ICON 8b trial patients
Change to current version
Criteria
Changes
N/A
Introduction of version control and addition of section re-SACT and monitoring
National Cancer Drugs Fund – Application Form 05 June 2015
Bevacizumab for Advanced Ovarian Cancer – 1st line
Page 1
National Cancer Drugs Fund Application Form –
Bevacizumab
for Advanced Ovarian Cancer
(1st line treatment)
Instructions to Consultants: Please fill in each section of the form electronically and save the
document with your own file name. [If you continue typing the boxes will enlarge to contain the text].
Please send electronically to ______________________. Please also send copies to your Trust’s link
accountant / corporate contracting team.
Security of Patient Identifiable Information: The patient will be identified by their NHS number only.
Please do not include any other patient identifiers for confidentiality reasons. All communication must be
sent to the Cancer Drugs Fund Office via secure e mail accounts: that is from an nhs.net account to the
____________ account.
Receipt of Application: The sender of the application will receive an acknowledgement, together with
details of the unique Cancer Drugs Fund reference.
Cancer Drugs Fund Policy: To check the status of a particular therapy please check the Cancer Drugs
Fund Policy at _________________
Applications will be subject to Clinical Audit arrangements.
BY TICKING THESE BOXES AND SUBMITTING THE APPLICATION THE CLINICIAN IS
CONFIRMING THE PATIENT MEETS ALL THE CRITERIA BELOW. IT SHOULD BE NOTED THAT
THE SACT DATASET WILL BE USED TO MONITOR THAT THESE CRITERIA ARE BEING MET.
Approved Treatment Required for Bevacizumab for Advanced Ovarian Cancer –
1st line
TICK
All 9 conditions must be met
1. Application made by and first cycle of systemic anti-cancer therapy to be
prescribed by a consultant specialist specifically trained and accredited in
the use of systemic anti-cancer therapy
2. Chemotherapy naïve advanced epithelial ovarian, fallopian tube or primary
peritoneal cancer (not licensed at this dosage)
3. 1st line indication
4. Patients must satisfy one of the following criteria:
i) FIGO stage III debulked but residual disease more than 1cm OR
ii) Stage IV disease OR
iii) Stage III at presentation and requiring neo-adjuvant chemotherapy due
to low likelihood of optimal primary surgical cytoreduction
5. Given with Carboplatin and Paclitaxel combination chemotherapy
6. Bevacizumab to start with:
i)
1st or 2nd cycle of chemotherapy following primary debulking surgery,
OR
ii)
1st or 2nd cycle of chemotherapy following interval debulking surgery
performed after 3 – 4 cycles of neo-adjuvant chemotherapy, OR
iii) 1st or 2nd cycles of chemotherapy for those patients with stage IV
disease or inoperable disease, OR
National Cancer Drugs Fund – Application Form 05 June 2015
Bevacizumab for Advanced Ovarian Cancer – 1st line
Page 2
iv) 1st cycle of neo-adjuvant chemotherapy
7. Bevacizumab dose to be 7.5mg/kg every 3 weeks
8. Maximum of 18 cycles of Bevacizumab
9. As neither this dosage of Bevacizumab nor its use in the neoadjuvant
setting is licensed in ovarian cancer it must be used within the treating
Trust's governance framework
Note: This policy is NOT for patients with stage I-III disease who have had optimal
debulking
Note: These criteria also apply to patients entered into the ICON 8b trial. Clinicians
should be aware that for patients randomised to the non-bevacizumab arm of ICON 8b,
the use of bevacizumab in subsequent lines of treatment is not approved under current
CDF criteria.
Consultant Approval (email authority)
Patient Consent Obtained (date of letter – copy to be retained on patient file)
National Cancer Drugs Fund – Application Form 05 June 2015
Bevacizumab for Advanced Ovarian Cancer – 1st line
Page 3
Proposed Start Date for Therapy (add clinic date)*:
Consultant details*
(including signature or
email confirmation)
Name:
Hospital:
Address:
Post Code:
Telephone:
Nhs.net
Trust Pharmacist details of the Trust where
the patient will be
treated*
Mandatory - NHS No*:
Mandatory – Patients
date of birth*
Optional – Hospital No.
Clinical Commissioning
Group*
Patient’s GP*
(name, address,
telephone)
Name:
Hospital:
Address:
Post Code:
Telephone:
Nhs.net
NHS No:
DOB:
Hospital No:
CCG Name:
Name:
Address:
Post Code:
ICD-10 Code*
C56 – Malignant neoplasm of ovary
HRG Code
Completion of items marked with * is mandatory. Failure to complete these items may
mean that payment is not made.
National Cancer Drugs Fund – Application Form 05 June 2015
Bevacizumab for Advanced Ovarian Cancer – 1st line
Page 4